Purchase Order 75F40126P00130

The Food and Drug Administration awarded a purchase order to Illumina, Inc. for one whole genome sequencing instrument on June 25, 2026, at a fixed price of $53,442.90. The procurement was conducted on a sole-source basis under FAR Part 12 as a commercial product acquisition. The order specifies an Illumina MiSeq i100 sequencing system with training for up to three personnel and a one-year manufacturer's warranty covering parts, labor, and operational support. The system must support...

The Department of Health and Human Services Food and Drug Administration awarded a $533,378 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract is for delivery of one Illumina NextSeq 2000 Sequencing System to support the agency's microbial metagenomics research in Berwyn Heights, Maryland. The original solicitation requested an integrated genomic sequencing system, including the NextSeq 2000 or equivalent, to generate sequence data, perform real-time...

The Food and Drug Administration awarded a $439,247.56 firm fixed-price purchase order to Illumina, Inc. on July 15, 2024, for the procurement of an Illumina NextSeq 2000 High Throughput Next-Generation Sequencing System. The award encompasses the sequencing instrument itself, trade-in credit for an existing NextSeq 500 unit, installation services, operator training, warranty coverage, and a preventative maintenance agreement. The system will be delivered to and installed at the FDA's Center for...

The Food and Drug Administration awarded a $233.7K firm fixed-price purchase order to Illumina, Inc. for an Illumina NextSeq 2000 Sequencing System plus one option year of post-warranty maintenance. The award was issued on June 17, 2024, with an ultimate completion date of July 23, 2026. The equipment will be delivered to and maintained at the FDA's National Center for Toxicological Research in Jefferson, Arkansas, though the place of performance is listed as Singapore. No set-aside...

<p>The Food and Drug Administration awarded a purchase order to Illumina, Inc. for an Illumina NovaSeq 6000 service contract valued at $780,844, effective June 4, 2024, with ultimate completion on September 26, 2029. Performance occurs in San Diego, California. The order covers maintenance and service for the NovaSeq 6000 sequencing instrument on a firm fixed-price basis with no set-aside designation.</p>

The Food and Drug Administration awarded a firm fixed price purchase order valued at $534,536 to Illumina, Inc., a San Diego-based biotechnology company specializing in genomic sequencing technologies, for one Illumina NextSeq 2000 Sequencer with post-warranty correction and remedial repair services. The contract, awarded on August 17, 2023, with an ultimate completion date of December 11, 2028, was issued under a combined synopsis/solicitation posted in May 2023. The sequencer will be delivered...

The Food and Drug Administration (FDA) awarded a delivery order contract to Illumina, Inc. for NextSeq reagent kits with a ceiling value of $59,243.80. Executed on May 18, 2016, with an ultimate completion date of September 13, 2017, this firm fixed-price delivery order utilized no set-aside designation and reflects Illumina's specialized capabilities in genomic sequencing consumables. The contract was performed at Illumina's San Diego, California location, where the company manufactures...

The Food and Drug Administration awarded a $534,031 firm fixed-price purchase order to Illumina, Inc. for one Illumina NextSeq 2000 High Throughput Next-Generation Sequencing System. This was a sole source award to the San Diego-based biotechnology company, with no set-aside designation applied. The equipment will be delivered to the FDA's facility in Silver Spring, Maryland, with a completion date of April 17, 2025. The Division of Applied Regulatory Science selected this system to enhance...

The Department of Health and Human Services Food and Drug Administration awarded a $169,505.48 firm fixed price purchase order to Illumina, Inc. of Laurel, Maryland for an Illumina NextSeq 50 System Check. The contract has a period of performance through February 10, 2025 to deliver product care services for the NextSeq 50 sequencing system. No set-aside provisions were applied to this award made by the FDA to support its regulatory and public health responsibilities through genomic analysis...

The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $341,700 purchase order to Illumina, Inc. to provide one (1) Illumina NextSeq 2000 System. The place of performance for this firm fixed price contract is Silver Spring, Maryland. The period of performance is from September 29, 2022 through October 29, 2023. The NextSeq 2000 System is a benchtop high-throughput sequencing platform that enables DNA and RNA sequencing applications. No applicable...